Enflonsia-Clesrovimab-Cfor
ENFLONSIA is a long-acting, preventive monoclonal antibody developed to protect infants against a broad range of respiratory syncytial virus (RSV) disease severity. This includes severe cases that may lead to hospitalization. It is the first and only RSV preventive option that offers a weight-independent, single-dose administration, simplifying protection across all infants regardless of size or […]
Avmapki Fakzynja Co-Pack-Avutometinib And Defactinib
Avmapki Fakzynja combines two oral kinase inhibitors for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer after prior systemic therapy. It targets both MEK and FAK pathways to help control tumor growth in patients with limited treatment options.
Emrelis-Telisotuzumab Vedotin-Tllv
Emrelis is an antibody‑drug conjugate for adults with locally advanced or metastatic non-squamous non-small cell lung cancer overexpressing c‑Met after prior therapy. It delivers targeted chemotherapy directly to cancer cells to inhibit tumor progression.
Penpulimab-Kcqx-Penpulimab-Kcqx
Penpulimab‑Kcqx is an intravenous PD‑1 inhibitor used with chemotherapy to treat recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. It boosts immune response to help control tumor growth in patients who have progressed after prior therapies.
Imaavy-Nipocalimab-Aahu
Imaavy is an IV antibody for adults and teens aged 12 and older with generalized myasthenia gravis who test positive for AChR or MuSK antibodies. It targets and blocks the FcRn receptor to reduce harmful autoantibodies and improve muscle strength.
Dawnzera-Donidalorsen
Dawnzera is an RNA-targeted antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It works by selectively reducing prekallikrein production, thereby lowering bradykinin formation, to significantly reduce the frequency and severity of swelling episodes. The drug is administered via a subcutaneous autoinjector every 4 weeks, […]
